MEDIWOUND LTD (MDWD) Stock Price & Overview
NASDAQ:MDWD • IL0011316309
Current stock price
The current stock price of MDWD is 17.35 USD. Today MDWD is down by -2.09%. In the past month the price increased by 2.3%. In the past year, price decreased by -4.04%.
MDWD Key Statistics
- Market Cap
- 222.948M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.10
- Dividend Yield
- N/A
MDWD Stock Performance
MDWD Stock Chart
MDWD Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to MDWD. When comparing the yearly performance of all stocks, MDWD is a bad performer in the overall market: 74.83% of all stocks are doing better.
MDWD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MDWD. MDWD has a bad profitability rating. Also its financial health evaluation is rather negative.
MDWD Earnings
On March 5, 2026 MDWD reported an EPS of -0.56 and a revenue of 1.87M. The company beat EPS expectations (13.08% surprise) and missed revenue expectations (-70.05% surprise).
MDWD Forecast & Estimates
12 analysts have analysed MDWD and the average price target is 30.4 USD. This implies a price increase of 75.19% is expected in the next year compared to the current price of 17.35.
For the next year, analysts expect an EPS growth of -33.65% and a revenue growth 16.75% for MDWD
MDWD Groups
Sector & Classification
MDWD Financial Highlights
Over the last trailing twelve months MDWD reported a non-GAAP Earnings per Share(EPS) of -2.1. The EPS increased by 31.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.68% | ||
| ROE | -54.73% | ||
| Debt/Equity | 0.19 |
MDWD Ownership
MDWD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.31 | 869.14B | ||
| JNJ | JOHNSON & JOHNSON | 18.19 | 555.642B | ||
| MRK | MERCK & CO. INC. | 23 | 289.223B | ||
| PFE | PFIZER INC | 9.21 | 156.544B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.34 | 120.728B | ||
| ZTS | ZOETIS INC | 17.35 | 51.606B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.54 | 28.443B | ||
| VTRS | VIATRIS INC | 5.96 | 17.315B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.51 | 11.825B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.651B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.206B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.087B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.4 | 4.929B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MDWD
Company Profile
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. ; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Company Info
IPO: 2014-03-20
MEDIWOUND LTD
42 Hayarkon Street
YAVNE 8122745 IL
CEO: Sharon Malka
Employees: 121
Phone: 972779714100
MEDIWOUND LTD / MDWD FAQ
What does MDWD do?
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. ; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Can you provide the latest stock price for MEDIWOUND LTD?
The current stock price of MDWD is 17.35 USD. The price decreased by -2.09% in the last trading session.
What is the dividend status of MEDIWOUND LTD?
MDWD does not pay a dividend.
How is the ChartMill rating for MEDIWOUND LTD?
MDWD has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for MDWD stock?
12 analysts have analysed MDWD and the average price target is 30.4 USD. This implies a price increase of 75.19% is expected in the next year compared to the current price of 17.35.
Can you provide the upcoming earnings date for MEDIWOUND LTD?
MEDIWOUND LTD (MDWD) will report earnings on 2026-05-19.